利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

8 条记录 (耗时 0.02 秒)

    TLR4 inhibitors for the treatment of human infectious and inflammatory disorders
    2.
    发明授权
    TLR4 inhibitors for the treatment of human infectious and inflammatory disorders 有权
    用于治疗人类感染性和炎症性疾病的TLR4抑制剂

    公开(公告)号：US09072760B2

    公开(公告)日：2015-07-07

    申请号：US13848809

    申请日：2013-03-22

    申请人： University of Pittsburgh—of the Commonwealth System of Higher Education

    发明人： Peter Wipf ,  Matthew D. Neal ,  Sodhi P. Chhinder ,  David J. Hackam

    IPC分类号： A01N43/04 ,  A61K31/70 ,  A61K31/7008 ,  A61K31/7034 ,  A61K31/7028

    CPC分类号： A61K31/7028 ,  A61K31/351 ,  A61K31/7008 ,  A61K31/7024 ,  A61K31/7034

    摘要： The present invention relates to methods of treating infectious, inflammatory and post-traumatic disorders by administering various compounds newly discovered to have TLR4 inhibitory activity. In addition to methods of treatment, the present invention further provides for pharmaceutical compositions comprising said compounds, together with a suitable pharmaceutical carrier. Because TLR4 is the most upstream receptor in the pro-inflammatory LPS signaling cascade, treatments of the invention, which inhibit or antagonize TLR4 action, may avoid the pitfalls associated with other cytokine inhibitors that act further down the pathway and accordingly play a less specific (and perhaps non-critical) role.

    摘要翻译： 本发明涉及通过施用新发现的具有TLR4抑制活性的各种化合物来治疗感染性，炎性和创伤后疾病的方法。 除了治疗方法之外，本发明还提供包含所述化合物以及合适的药物载体的药物组合物。 因为TLR4是促炎性LPS信号级联中最上游的受体，因此抑制或拮抗TLR4作用的本发明的治疗可以避免与其他细胞因子抑制剂相关的陷阱，其进一步沿着该途径起作用并因此发挥较少的特异性 也许是非关键的）角色。

    NOVEL TLR4 INHIBITORS FOR THE TREATMENT OF HUMAN INFECTIOUS AND INFLAMMATORY DISORDERS
    4.
    发明申请
    NOVEL TLR4 INHIBITORS FOR THE TREATMENT OF HUMAN INFECTIOUS AND INFLAMMATORY DISORDERS 有权
    新型TLR4抑制剂治疗人类感染性和炎症性疾病

    公开(公告)号：US20150250809A1

    公开(公告)日：2015-09-10

    申请号：US14717349

    申请日：2015-05-20

    申请人： University of Pittsburgh - of the Commonwealth System of Higher Education

    发明人： Peter Wipf ,  Matthew D. Neal ,  Sodhi P. Chhinder ,  David J. Hackam

    IPC分类号： A61K31/7024 ,  A61K31/7034 ,  A61K31/7028

    CPC分类号： A61K31/7028 ,  A61K31/351 ,  A61K31/7008 ,  A61K31/7024 ,  A61K31/7034

    摘要： The present invention relates to methods of treating infectious, inflammatory and post-traumatic disorders by administering various compounds newly discovered to have TLR4 inhibitory activity. In addition to methods of treatment, the present invention further provides for pharmaceutical compositions comprising said compounds, together with a suitable pharmaceutical carrier. Because TLR4 is the most upstream receptor in the pro-inflammatory LPS signaling cascade, treatments of the invention, which inhibit or antagonize TLR4 action, may avoid the pitfalls associated with other cytokine inhibitors that act further down the pathway and accordingly play a less specific (and perhaps non-critical) role.

    摘要翻译： 本发明涉及通过施用新发现的具有TLR4抑制活性的各种化合物来治疗感染性，炎性和创伤后疾病的方法。 除了治疗方法之外，本发明还提供包含所述化合物以及合适的药物载体的药物组合物。 因为TLR4是促炎性LPS信号级联中最上游的受体，因此抑制或拮抗TLR4作用的本发明的治疗可以避免与其他细胞因子抑制剂相关的陷阱，其进一步沿着该途径起作用并因此发挥较少的特异性 也许是非关键的）角色。

    TLR4 inhibitors for the treatment of human infectious and inflammatory disorders
    7.
    发明授权
    TLR4 inhibitors for the treatment of human infectious and inflammatory disorders 有权
    用于治疗人类感染性和炎症性疾病的TLR4抑制剂

    公开(公告)号：US09532999B2

    公开(公告)日：2017-01-03

    申请号：US14717349

    申请日：2015-05-20

    申请人： University of Pittsburgh—of the Commonwealth System of Higher Education

    发明人： Peter Wipf ,  Matthew D. Neal ,  Sodhi P. Chhinder ,  David J. Hackam

    IPC分类号： A01N43/04 ,  A61K31/70 ,  A61K31/7024 ,  A61K31/7008 ,  A61K31/7034 ,  A61K31/7028

    CPC分类号： A61K31/7028 ,  A61K31/351 ,  A61K31/7008 ,  A61K31/7024 ,  A61K31/7034

    摘要： The present invention relates to methods of treating infectious, inflammatory and post-traumatic disorders by administering various compounds newly discovered to have TLR4 inhibitory activity. In addition to methods of treatment, the present invention further provides for pharmaceutical compositions comprising said compounds, together with a suitable pharmaceutical carrier. Because TLR4 is the most upstream receptor in the pro-inflammatory LPS signaling cascade, treatments of the invention, which inhibit or antagonize TLR4 action, may avoid the pitfalls associated with other cytokine inhibitors that act further down the pathway and accordingly play a less specific (and perhaps non-critical) role.

    摘要翻译： 本发明涉及通过施用新发现的具有TLR4抑制活性的各种化合物来治疗感染性，炎性和创伤后疾病的方法。 除了治疗方法之外，本发明还提供包含所述化合物以及合适的药物载体的药物组合物。 因为TLR4是促炎性LPS信号级联中最上游的受体，因此抑制或拮抗TLR4作用的本发明的治疗可以避免与其他细胞因子抑制剂相关的陷阱，其进一步沿着该途径起作用并因此发挥较少的特异性 也许是非关键的）角色。